Since 2020, Eli Lilly's stock has soared 603.43%, reaching $930, turning it from a $100 billion to a $740 billion company, revealing enormous growth potential.
While past growth rates might inform some experts, a forward-looking approach to Eli Lilly's projected revenue and net income over the next 3-5 years reveals a brighter future.
Eli Lilly's recent partnerships with Insitro and Qinotto align with innovative drug development strategies, enhancing their capabilities in metabolic diseases and brain-targeted therapies.
With a positive analyst rating and a price target increase to $1,025, Eli Lilly's stock outlook is bolstered by resolving supply issues for important drugs.
Collection
[
|
...
]